ARIEL3 introduced tumour homologous recombination deficiency (HRD) as an additional predictive marker for PARP inhibitors, with significant PFS benefits for both BRCA1/2 pathogenic variant carriers and patients with tumour HRD [10]. Here, BRCA1 is linked to neoplasm.